Cobertura vacunal contra hepatitis B en pacientes con diabetes mellitus by Arrelias, Clarissa Cordeiro Alves et al.
253
Arrelias CCA, Bellissimo-Rodrigues F, Lima LCL, Silva AS, Lima NKC, Zanetti ML
www.ee.usp.br/reeusp Rev Esc Enferm USP · 2016;50(2):253-260
1 Universidade de São Paulo, Escola de 
Enfermagem de Ribeirão Preto, Ribeirão Preto, 
SP, Brazil.
2 Universidade de São Paulo, Faculdade de 
Medicina de Ribeirão Preto, Ribeirão Preto, SP, 
Brazil.
Received: 10/17/2015
Approved: 09/04/2016 
Original article DOI: http://dx.doi.org/10.1590/S0080-623420160000200011
Corresponding author:
Clarissa Cordeiro Alves Arrelias 
Escola de Enfermagem de Ribeirão Preto, 
Universidade de São Paulo
Avenida Bandeirantes, 3900 
Campus Universitário
CEP 14040-902 – Ribeirão Preto, SP, Brazil
claarrelias@usp.br
abstract
Objective: Analyze the factors associated with full hepatitis B vaccination (three doses) 
in patients with diabetes mellitus. Method: Cross-sectional study, conducted in a health 
unit in a city in the state of São Paulo, with 255 patients on outpatient follow-up, in 2014. 
Data were obtained from the computerized system of the Municipal Health Department 
and via a structured questionnaire. A logistic regression model was used for analysis. 
Results: Full hepatitis B vaccination was noted in 13.7% of the patients and shown to be 
directly associated with their educational level (OR=1.30; CI: 1.07-1.57) and current or 
previous work as a health professional (OR=3.21; CI: 1.16-8.89). Conclusion: Hepatitis 
B vaccination coverage was found to be low in patients with diabetes mellitus, indicating 
their vulnerability to this serious and potentially fatal disease. Higher educational level 
and working in the field of health were associated with better vaccination coverage.
descriPtOrs
Hepatitis B; Immunization Coverage; Diabetes Mellitus; Educational Status; Health 
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INTRODUCTION
Patients with diabetes mellitus (DM) constitute a 
recognized risk group for hepatitis B and C due to the 
invasive procedures needed to treat and control their dis-
ease. These procedures can lead to situations where sy-
ringes, needles and blood glucose monitoring devices are 
shared(1-3). The literature describes various outbreaks of 
hepatitis B in DM patients(3-5).
In 2011, the Advisory Committee on Immunization 
Practices of the Centers for Disease Control and Prevention 
(CDC) in the United States, recommended, based on evi-
dence, hepatitis B vaccination for DM patients from ages 
19 to 59, once a diagnosis is made, and for those aged 60 
and older, after assessment of the risk and likelihood of an 
adequate immune response to vaccination(6).
Hepatitis B vaccination has gradually been imple-
mented in Brazil by the National Immunization Program 
of the Ministry of Health, since 1989, in some regions 
and for groups considered to be at risk of infection. In 
1996, the vaccine started being distributed throughout 
Brazil for children under age one. Its extension to the 
population under age 20 occurred in 2001 and, in 2011, 
for the 20-24 age range. In January 2012, it included 
those up to age 29, and in 2013, up to age 49(7-8). In 2016, 
free provision of the hepatitis B vaccine was expanded to 
cover the entire population regardless of age or vulner-
ability(9). Traditional immunization against the hepatitis 
B virus (HBV) entails three doses of the vaccine via in-
tramuscular injection, with a minimum interval of one 
month between the first and second dose, and six months 
between the first and third dose(10). 
The Brazilian Immunization Society recommends that 
DM patients be immunized with the hepatitis B vac-
cine(11). However, in the National Immunization Program 
of the Ministry of Health, DM patients are still not rec-
ognized as being a vulnerable group, and there is no spe-
cific recommendation for vaccination against the disease. 
It is worth noting that the hepatitis B vaccine is effective 
in preventing the infection and is recommended for DM 
patients regardless of the type of diabetes. The immune 
response to the vaccine in younger patients is similar to 
those with or without DM. However, for DM patients 
over age 40, the immune response is lower in relation to 
those without DM(2,6).
In the international literature, there are few studies on 
vaccination coverage for DM patients. Studies conducted 
in the USA show that hepatitis B vaccination coverage in 
the DM population is still low as compared to individuals 
without the disease(12-14).  
In the national literature, there are studies on hepatitis B 
vaccination coverage for other populations, such as nursing 
babies, people under age 25, health professionals, illicit drug 
users, sex workers and health students(15-23). However, there 
is a shortage of knowledge regarding recommended hepa-
titis B vaccination coverage for the population with DM.
Considering that DM patients represent a population 
with higher risk of contracting hepatitis B, the objective of 
this study was to examine the factors associated with full 
hepatitis B vaccination (three doses) in DM patients receiv-
ing outpatient follow-up in a city in the state of São Paulo.
METHOD
A quantitative, observational, cross-sectional study 
was conducted from July to December 2014, in a District 
Basic Health Unit, in a city in the state of São Paulo. 
The target population consisted of 741 DM patients, 
both men and women, 18 years of age or over, receiving 
follow-up in secondary care outpatient units (Integrated 
Outpatient Clinic or Endocrinology Outpatient Clinic) 
in the aforementioned health unit. 
Patients who had hearing and cognitive ability to 
answer the questions in the data collection instrument 
and who freely consented to participate in the study were 
included. Of the 741 potential candidates, 419 were in 
active follow-up and had a medical appointment sched-
uled in the period from July to December 2014. Of these, 
122 missed their appointments, 35 refused to participate 
in the study and seven were excluded due to some level 
of cognitive impairment. The convenience sample con-
sisted of 255 DM patients who showed up for their medi-
cal appointment in the Integrated Outpatient Clinic or 
Endocrinology Outpatient Clinic, from July to December 
2014, and met the inclusion criteria, representing 60.9% 
of the population of DM patients in active follow-up, in 
2014, in the aforementioned study location.
A questionnaire was used for data collection, containing 
demographic variables (gender, age and education); clini-
cal variables (length of time with DM, insulin use, blood 
glucose monitoring, hepatitis B vaccination recommenda-
tion), and those related to vaccination coverage (number of 
hepatitis B vaccine doses registered and those reported by 
the patient). The data related to the demographic, clinical 
and reported vaccination coverage variables were collected 
through interviews with patients, and the data correspond-
ing to the number of doses, by consulting the vaccina-
tion records from the computerized Health Management 
System (Hygia Web), implemented in the city in 1994 and 
which interconnects all the units in the health care net-
work. The system allows professionals to register each dose 
given. The doses given before the system’s implementation 
can be registered through presentation of the patient's vac-
cination card. Patients with a hepatitis B vaccination rec-
ommendation were defined as those who reported a job 
activity, such as a health professional, police officer, cor-
rections officer, jailer, residential or hospital trash collec-
tor, manicurist, pedicurist or podiatrist and/or people with 
risk behaviors. Risk behavior was defined as current or past 
sexual or domestic contact with individuals with hepatitis 
B, who smoked, inhaled or injected drugs, with a history of 
sexually communicable diseases and blood or blood product 
transfusions. Patients with records of at least three hepatitis 
B vaccine doses were considered to have received full vac-
cination coverage.
Data were collected by two researchers previous-
ly trained on how to approach patients and apply the 
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instrument. The researchers were in immersion for 12 
days. This period was necessary to acquire knowledge 
about the care dynamics, available infrastructure and 
health professionals in the outpatient clinics. The activi-
ties were carried out in two stages.
Stage 1: DM patients were recruited through sched-
uled medical appointments. Every week the researcher 
checked the agenda for names of potential patients to 
be part of the study sample. With the list of potential 
patients in hand, on the scheduled day of the medical ap-
pointment, the researcher confirmed through the health 
records those diagnosed with DM. At the end of medical 
visit, the researcher introduced himself to the patient and 
presented the objectives and nature of the research. Those 
who agreed to participate were asked to sign two copies 
of a free and informed consent form - one for the re-
searcher and the other for the patient. Data were collected 
by the researcher in a reserved room from Monday to 
Friday, during the afternoon in the Integrated Outpatient 
Clinic, and Tuesdays and Thursdays, during the morning 
and afternoon in the Endocrinology Outpatient Clinic. 
Average interview time was 15 minutes. The answers were 
transcribed in the instrument itself. 
Second stage: access to the Hygia Web system to 
obtain data regarding the number of hepatitis B vaccine 
doses received by DM patients. The data were recorded 
in the data collection instrument. The computers in the 
health unit were used. 
For statistical analysis of the data, STATA 11.0 
(Statacorp LP, College Station, United States) was 
used. Data were described by means of descriptive sta-
tistics and presented in absolute numbers and percent-
ages. Univariate analysis of possible associations among 
the variables – demographic, clinical and full hepatitis B 
vaccination (three doses) – was determined by the Chi-
square test with Pearson's correction, Fisher's exact test 
(bicaudal) and the Wilcoxon-Mann-Whitney test. For 
multivariate analysis of possible associations among se-
lected variables – demographic (gender, age, education 
and profession), clinical (length of time diagnosed with 
DM, insulin use and blood glucose monitoring) and full 
hepatitis B vaccination endpoint (three doses) – a logis-
tic regression model was built. The variables included in 
the model were those which manifested a possible as-
sociation with the endpoint variable in the univariate 
analysis (p≤0.20). Independent variables were included 
in the model in an ordered way according to the signifi-
cance level (p-value) obtained in the univariate analysis. 
P-values lower than 5% were considered significant for 
all analyses (a=0.05). 
The research project was approved by the Research 
Ethics Committee of the Ribeirão Preto College of 
Nursing at the Universidade de São Paulo. Protocol: 
24638213.2.0000.5393.
RESULTS 
The characterization of the patients studied is found 
in Table 1. 
Table 1 – Numerical and percentage distribution of DM patients 
according to demographic, clinical and hepatitis B vaccination 
coverage variables – Ribeirão Preto, São Paulo, Brazil, 2014.
Variables n %
gender 
Male 85 33.3
Female 170 66.7
age  
≤ 49 years 35 13.8
> 49 years 220 86.2
education 
None 9 3.5
Adult literacy 2 0.8
1st - 4th Incomplete elementary education 51 20.0
1st - 4th Complete elementary education 69 27.1
5th - 8th Incomplete secondary education 26 10.2
5th - 8th Complete secondary education 31 12.2
Incomplete high school 8 3.1
Complete high school 39 15.3
Incomplete higher education 10 3.9
Complete higher education 10 3.9
length of time with diabetes (years)
<1 9 3.5
1-10 129 50.6
11-20 71 27.8
21-30 35 13.7
31-40 10 3.9
51-60 1 0.4
insulin use
Yes 150 58.8
No 105 41.2
blood glucose monitoring
Yes 190 74.5
No 65 25.5
Health professional
Yes 25 9.8
No 230 90.2
Police officer/corrections officer/jailer
Yes 5 1.6
No 250 98.4
residential/hospital trash collection worker
Yes 8 3.1
No 247 96.9
Manicurist/pedicurist/podiatrist
Yes 12 4.7
No 243 95.3
risk behaviora
Yes 197 77.3
No 58 22.7
aCurrent or past sexual or domestic contact with individuals with hepatitis B, hav-
ing smoked, inhaled or injected drugs, having a history of sexually communicable 
diseases and blood or blood product transfusions.
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Table 2 presents the number of hepatitis B vaccine 
doses reported by DM patients and the number according 
to the records in the computerized system of the unit. Full 
table 2 – Number of registered hepatitis B vaccine doses according to the number of doses reported by the patient – Ribeirão Preto, 
São Paulo, Brazil, 2014.
reported doses
registered doses
no record 1 or 2(incomplete)
≥ 3 
(complete)  total
n % n % n % n %
None 80 96.4 1 1.2 2 2.4 83 100
1 or 2 1 10.0 5 50.0 4 40.0 10 100
≥ 3 10 31.3 2 6.2 20 62.5 32 100
Does not know number of doses 20 69.0 2 6.9 7 24.1 29 100
Does know if was vaccinated 97 96.0 0 0.0 4 4.0 101 100
total 208 81.6 12 4.7 35 13.7 255 100
hepatitis B vaccination was observed in 13.7%; for 4.7% 
it was incomplete; and 81.6% did not have any vaccina-
tions registered.  
Table 3 shows that the age median was lower among 
patients with full hepatitis B vaccination compared to 
the others (60 and 64 years, respectively, p=0.003). Full 
vaccination was associated with completion of univer-
sity (p<0.001) and current or previous work as a health 
professional  (p=0.001). 
No significant association was found between full hepa-
titis B vaccination and gender, length of time with DM, 
insulin use, blood glucose monitoring, other job activities 
investigated and risk behaviors (Table 3). 
continued...
Table 3 – Hepatitis B vaccination coverage according to demographic and clinical variables examined – Ribeirão Preto, São Paulo, 
Brazil, 2014.
Variables
registered doses 
< 3 a ≥ 3
pb Or (ci 95%)
n % n %
gender 
Male 74 87.1 11 12.9 1.00
Female 146 85.9 24 14.1 0.797 1.10 (0.51-2.38)
age  
Median (p25-p75) 64 (57-71) 60 (47-65) 0.003 –
≤ 49 years 23 65.7 12 34.3
> 49 years 197 89.5 23 10.5
education 
None 9 100.0 0 0.0
Adult literacy 1 50.0 1 50.0
1st – 4th Incomplete elementary 47 92.2 4 7.8
1st – 4th Complete elementary 64 92.8 5 7.2
5th – 8th Incomplete secondary 24 92.3 2 7.7
5th – 8th Complete secondary 28 90.3 3 9.7
Incomplete high school 5 62.5 3 37.5
Complete high school 28 71.8 11 28.2
Incomplete higher education 8 80.0 2 20.0
Complete higher education 6 60.0 4 40.0 <0.001 –
length of time with diabetes
<1 7 77.8 2 22.2
1-10 113 87.6 16 12.4
11-20 59 83.1 12 16.9
21-30 30 85.7 5 14.3
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In the logistic regression analysis (Table 4), full hepati-
tis B vaccination was directly associated with the patient’s 
educational level (OR=1.26; CI: 1.03-1.53) and current or 
previous work as a health professional (OR=3.21; CI: 1.16-
8.89), but not with age (OR=0.97; CI: 0.93-1.01), unlike 
the findings in the univariate analysis. 
Table 4 – Logistic regression model for hepatitis B vaccination coverage (≥ 3 doses) – Ribeirão Preto, São Paulo, Brazil, 2014.
Variables     Or (ci 95%) p standard error
Female 1.45 (0.61-3.41) 0.391 0.63
Age 0.97 (0.93-1.01) 0.175 0.01
Education 1.26 (1.03-1.53) 0.020 0.12
Length of time with DM 0.99 (0.94-1.04) 0.809 0.02
Insulin use 11.1 (0.38-3.21) 0.846 0.60
Blood glucose monitoring 1.56 (0.43-5.61) 0.489 1.02
Health professional 3.21 (1.16-8.89) 0.024 1.66
OR: odds ratio; each variable was adjusted to the other six.
Variables
registered doses 
< 3 a ≥ 3
pb Or (ci 95%)
n % n %
31-40 10 100.0 0 0.0
51-60 1 100.0 0 0.0 0.865 –
insulin use
No 94 89.5 11 10.5 1.00
Yes 126 84.0 24 16.0 0.207 1.62 (0.75-3.48)
blood glucose monitoring
No 60 92.3 5 7.7 1.00
Yes 160 84.2 30 15.8 0.102 2.25 (0.83-6.06)
Health professional
No 204 88.7 26 11.3 1.00
Yes 16 64.0 9 36.0 0.001 4.41 (1.77-10.99)
Police officer/corrections officer/jailer
No 216 86.4 34 13.6 1.00
Yes 4 80.0 1 20.0 0.683 1.58 (0.17-14.6)
residential/hospital trash collection worker
No 212 85.8 35 14.2
Yes 8 100.0 0 0.0 0.604 –
Manicurist/pedicurist/podiatrist
No 210 86.4 33 13.6 1.00
Yes 10 83.3 2 16.7 0.762 1.27 (0.26-6.06)
risk behaviorc
No 170 86.3 27 13.7 1.00
Yes 50 86.2 8 13.8 0.986 1.00 (0.43-2.35)
aPatients with one, two or no doses registered.
bPearson chi-square test (gender, insulin use, blood glucose monitoring, health professional, risk behavior; Fisher’s exact test (Police officer/corrections officer/jailer; Residen-
tial/hospital trash collection worker; Manicurist/pedicurist/podiatrist), Wilcoxon-Mann-Whitney test (Age, education, length of time with DM).
cCurrent or past sexual or domestic contact with individuals with hepatitis B, having smoked, inhaled or injected drugs, having a history of sexually communicable diseases 
and blood or blood product transfusions.
...continuation
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DISCUSSION
The proposed design for performing the study does 
not enable establishing cause and effect relationships 
between vaccination coverage and the variables examined. 
However, it is possible through the results to obtain the 
hepatitis B vaccination diagnosis among DM patients. 
The demographic and clinical characteristics of the sam-
ple studied are consistent with two cross-sectional studies 
with DM patients receiving outpatient care in the city that 
was investigated(24-25).
Full vaccination found was 13.7%, lower than in a retro-
spective study conducted with a non-institutionalized popula-
tion in the USA, which showed that hepatitis B vaccination 
rates were 22.4% from 1999 to 2008(14). However, another 
study conducted with a non-institutionalized DM popula-
tion sample in the USA in 2009(12) found that full hepatitis 
B vaccination was 16.6%, close to the results in this study. In 
relation to the incomplete vaccination scheme, the proportion 
of DM patients who had received one or two doses of the 
vaccine (19.5%) was higher, when compared with this study 
(4.7%). The proportion of DM patients with no vaccinations 
registered (81.6%) was also higher in comparison to the study 
conducted in the USA, in 2009 (63.9%)(12). 
Full hepatitis B vaccination has increased in the DM 
population. A study conducted with a non-institutional-
ized population sample in the USA, in 2015, found that full 
hepatitis B vaccination was 17.1%(13). These results show a 
slight increase in full vaccination in relation to the study 
conducted in 2009, and that adhesion to the hepatitis B 
vaccination recommendation for DM patients is still low(12-
13). In this regard, future studies are needed to investigate 
the factors which interfere with achieving the hepatitis B 
vaccination goals for people with DM.
It is important to emphasize that, in Brazil, the impor-
tance of hepatitis B vaccinations for people with DM is not 
much disseminated, unlike the influenza vaccine, where DM 
is included as a risk category for influenza, and is recommend-
ed and available for people with DM. A population-based 
study conducted among older people in the city of Campinas, 
state of São Paulo, from 2008 to 2009, found an association 
between diabetes and annual influenza vaccination(26).
In comparing the number of hepatitis B doses reported 
by DM patients and those registered in the Hygia Web 
System, of the patients who reported not having received 
any vaccine dose, 96.4% did not have any vaccination regis-
tered. This shows a high correlation between the informa-
tion reported and the data registered. In relation to those 
who reported not knowing whether they had been vaccinat-
ed, 96% did not have any vaccination registered and among 
those who reported not knowing the number of doses re-
ceived, 69% did not have anything registered in the system. 
Of the patients who reported an incomplete vaccination 
scheme, it was registered in one half of the cases, whereas 
for the full scheme, it was registered in 40% of the cases. 
These results may reflect the patients’ lack of information 
regarding the importance of hepatitis B vaccination for DM 
patients, or difficulty remembering if they had received the 
hepatitis B vaccination or not, as well as report the num-
ber of doses received. However, it cannot be presumed that 
information alone will modify attitudes toward protection 
against hepatitis B. In this regard, having health profession-
als monitor the vaccination calendar of DM patients could 
be an effective strategy in diabetes education. 
Of the patients who reported a full vaccination scheme, it 
was also registered in 62.5% of the cases and in 31.3% it was 
not. Possible losses of records related to the time and place 
where the DM patient was vaccinated represents a challenge 
for health services to improve and expand health information 
systems, and is one of the priorities in nursing research(27). 
In examining the variables related to full vaccination, 
an association was found between younger ages and vac-
cination. Full vaccination was 34.3% among patients 49 
years of age and less, as opposed to 10.5% for those over 
49. However, the association between age and full hepatitis 
B vaccination was not confirmed after the logistic regres-
sion analysis, concurring with a similar study conducted in 
the USA, in 2009(12). In Brazil, during the period in which 
the study data were collected, hepatitis B vaccination was 
recommended and available for the adult population up to 
age 49, which could explain the greater prevalence of vac-
cination in patients aged 49 and under. 
On the other hand, it was found that educational level 
is directly linked to hepatitis B coverage, which coincides 
with a similar study conducted in the USA, in 2009(12). The 
importance of information for DM patients about the hep-
atitis vaccination scheme is an effective and accessible way 
to prevent infection. Patients with lower educational levels, 
older ages and receiving DM follow-up need special atten-
tion due to the complexity of the treatment. The hepatitis 
vaccination scheme, since it is comprised of three doses, is 
difficult for patients to understand and follow, causing many 
to abandon the proposed vaccination scheme. In this regard, 
the hepatitis B vaccination scheme needs to be reinforced 
with DM patients during their visits with health profession-
als, as well as be followed up until the vaccination scheme 
is completed. Therefore, it is recommended that hepatitis B 
vaccination be included in a list of information provided to 
DM patients, particularly those who use insulin, monitor 
blood glucose and are subject to other risk factors. 
There was also an association between working as a 
health professional, whether currently or in the past, and 
full hepatitis vaccination, as found in a similar study con-
ducted in the USA, in 2009(12). Hepatitis B vaccination is 
recommended for health professionals and available in the 
public health system for any age range, which may explain 
these results(28-29). 
The results obtained serve as a starting point for future 
studies related to the importance of immunization for DM 
patients and training of nursing care professionals, since 
these represent a risk population for infection by the hepa-
titis B virus(1-3,30).
A limitation of the study regards the data source (the 
computerized Health Management System), since, in the 
sample studied, DM patients vaccinated before 1994 or in 
other cities and who do not have a vaccination card may 
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underestimate the recommendation for full hepatitis vac-
cination. However, these situations are not very likely, since 
the study sample is predominantly elderly and the avail-
ability of the vaccine for adults, recent.
CONCLUSION
Hepatitis B vaccination coverage was found to be low in 
DM patients, indicating their vulnerability to this serious 
and potentially fatal disease. Higher educational level and 
working in the health field were associated with better vac-
cination coverage. This data reveals the urgent need to in-
clude DM patients in the National Immunization Program 
as a priority group for hepatitis B vaccination. This study 
provides important input for evaluating the clinical prac-
tices of primary health care nurses in providing care related 
to vaccination coverage for people with diabetes mellitus. 
resUMO
Objetivo: Analisar os fatores associados à vacinação completa contra hepatite B (3 doses) em pacientes com diabetes mellitus. Método: 
Estudo transversal, realizado em uma Unidade de Saúde, de uma cidade do interior paulista, com 255 pacientes em seguimento 
ambulatorial, em 2014. Os dados foram obtidos no sistema informatizado da Secretaria Municipal de Saúde e por meio de um 
questionário estruturado e, para análise, modelo de regressão logística. Resultados: Vacinação completa contra hepatite B foi observada 
em 13,7% dos pacientes e mostrou-se diretamente associada ao nível de escolaridade (OR=1,30; IC: 1,07-1,57) e ao trabalho atual ou 
pregresso como profissional da saúde (OR=3,21; IC: 1,16-8,89). Conclusão: A cobertura vacinal contra hepatite B mostrou-se baixa 
em pacientes com diabetes mellitus, evidenciando a vulnerabilidade a essa doença grave e potencialmente fatal. Maior escolaridade e o 
trabalho na área da saúde foram associados a melhor cobertura vacinal.
descritOres
Hepatite B; Cobertura Vacinal; Diabetes Mellitus; Escolaridade; Pessoal de Saúde.
resUMen
Objetivo: Analizar los factores asociados con la vacunación completa contra hepatitis B (3 dosis) en pacientes con diabetes mellitus. 
Método: Estudios transversal, llevado a cabo en una Unidad de Salud de una ciudad del interior paulista, con 255 pacientes en 
seguimiento ambulatorio, en 2014. Los datos fueron obtenidos en el sistema informatizado de la Secretaría Municipal de Salud y 
mediante un cuestionario estructurado y, para el análisis, un modelo de regresión logística. Resultados: Vacunación completa contra 
hepatitis B fue observada en el 13,7% de los pacientes y se mostró directamente asociada con el nivel de escolaridad (OR=1,30; IC: 1,07-
1,57) y con el trabajo actual o anterior como profesional sanitario (OR=3,21; IC: 1,16-8,89). Conclusión: La cobertura vacunal contra 
hepatitis B se mostró baja en pacientes con diabetes mellitus, evidenciándose la vulnerabilidad a esa enfermedad severa y potencialmente 
fatal. Mayor escolaridad y el trabajo en el área sanitaria estuvieron asociados con la mejor cobertura vacunal.
descriPtOres
Hepatitis B; Cobertura de Vacunación; Diabetes Mellitus; Escolaridad; Personal de Salud.
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